Onco360(R) Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
LOUISVILLE, Ky., Jan. 07, 2026 (GLOBE NEWSWIRE) — Onco360(R), the nation's leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy partner for TAVALISSE(R) (fostamatinib disodium hexahydrate), GAVRETO(R) (pralsetinib), and REZLIDHIA(R) (olutasidenib). “We are looking forward to serving as one of Rigel Pharmaceuticals' national specialty pharmacy providers and expanding our […]